mProX™ Human RPS6KA1 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

RPS6KA1, a member of the RSK gene family, has various applications in different fields. In the context of acute myeloid leukemia (AML), RPS6KA1 and other RSK gene family members can be used to predict prognosis and treatment responses. They can help classify patients into different risk groups and determine overall survival rates. Additionally, RPS6KA1 may serve as a potential drug target for AML treatment. In the field of cancer treatment, RPS6KA1 has been implicated in resistance to therapy in AML. Inhibiting RPS6KA1 can enhance the sensitivity of cancer cells to this combination therapy. Furthermore, RPS6KA1 inhibition can target specific subclones of cancer cells and prevent relapse. In pancreatic and liver cancer, blocking miR-1976, which is regulated by RPS6KA1, can enhance chemosensitivity and improve treatment outcomes. In hepatocellular carcinoma (HCC), copy number variation (CNV) of RPS6KB1, along with BCL9, detected from circulating free DNA, can be used as prognostic markers and independent predictors of patient survival. Finally, in the field of cognitive decline, environmental enrichment, which includes physical, social, and mental activities, can improve cognitive abilities in aged mice. Late-onset environmental enrichment can restore deficits in spatial learning and memory in older mice, and this improvement is associated with specific changes in the hippocampal transcriptome, including the regulation of RPS6KA1. Overall, RPS6KA1 has diverse applications in the fields of leukemia, cancer treatment, hepatocellular carcinoma, and cognitive decline.